We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
CABAZITAXEL-DR.REDDY'S, CABAZITAXEL-DRLA, CABAZITAXEL-RZ, CABAZITAXEL-REDDY'S (Dr Reddys Laboratories Australia Pty Ltd)
Product name
CABAZITAXEL-DR.REDDY'S, CABAZITAXEL-DRLA, CABAZITAXEL-RZ, CABAZITAXEL-REDDY'S
Date registered
Evaluation commenced
Decision date
Approval time
254 working days (255)
Active ingredients
Cabazitaxel
Registration type
New generic medicine
Indication
CABAZITAXEL-DR.REDDY'S, CABAZITAXEL-DRLA, CABAZITAXEL-RZ, CABAZITAXEL-REDDY'S (injection) in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration resistant prostate cancer previously treated with a docetaxel containing regimen.